FPL-55712
FPL-55712 is a chemical compound that has been studied for its potential pharmacological effects, particularly as a leukotriene receptor antagonist. Leukotrienes are inflammatory mediators that play a significant role in conditions such as asthma and allergic rhinitis. FPL-55712 was one of the early compounds investigated for its ability to block the effects of leukotrienes, thereby reducing inflammation and bronchoconstriction.
Pharmacology[edit | edit source]
FPL-55712 functions primarily as a leukotriene receptor antagonist. It binds to leukotriene receptors, preventing leukotrienes from exerting their effects on target tissues. This action can lead to a reduction in inflammation and bronchoconstriction, which are common features in respiratory conditions like asthma.
Mechanism of Action[edit | edit source]
Leukotrienes are derived from arachidonic acid through the lipoxygenase pathway. They are potent mediators of inflammation and are involved in the pathophysiology of asthma by causing bronchoconstriction, increased vascular permeability, and mucus secretion. FPL-55712 inhibits the binding of leukotrienes to their receptors, thereby mitigating these effects.
Clinical Applications[edit | edit source]
While FPL-55712 showed promise in preclinical studies, its clinical use has been limited. The development of more potent and selective leukotriene receptor antagonists, such as Montelukast and Zafirlukast, has overshadowed the use of FPL-55712 in clinical settings.
Research and Development[edit | edit source]
FPL-55712 was one of the first compounds to demonstrate the potential therapeutic benefits of leukotriene receptor antagonism. Its development paved the way for the discovery and clinical use of more effective leukotriene receptor antagonists. Research on FPL-55712 has contributed to a better understanding of the role of leukotrienes in inflammatory diseases.
Safety and Efficacy[edit | edit source]
The safety profile of FPL-55712 was evaluated in early studies, but it did not progress to widespread clinical use. The compound's efficacy in reducing leukotriene-mediated effects was established in laboratory settings, but clinical trials with newer agents have shown superior results.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD